Biosciences' lead drug candidate, VE303, has been reported to demonstrate efficacy in preventing recurrent Clostridioides ...

Vedanta Biosciences has published additional results from its Phase 2 CONSORTIUM study for VE303, a potential first-in-class ...

Vedanta Biosciences is a clinical-stage biopharmaceutical company developing medicines for the treatment of gastrointestinal diseases. The company’s lead assets are potential first-in-class oral ...

US biotech Vedanta Biosciences has been awarded up to $76.9 million to develop VE303 for high-risk Clostridioides difficile (C. diff.) infection by a US government agency.

PureTech Health (PRTC) noted that its founded entity, Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia ...

Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases, today announced the publication of additional results ...

Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases, today announced the publication of additional results from ...

Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases, today announced the publication of additional results ...

CAMBRIDGE, Mass., January 23, 2025--(BUSINESS WIRE)--Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases ...

Topline data for the ongoing Phase 3 pivotal RESTORATiVE303 study are expected in 2026 ...